Florida Nurse Practitioner Barred from Handling Controlled Substances Over Exclusion
Published Date: 1/15/2026
Notice
Summary
Honorata Anna Itaman, a nurse practitioner from Florida, tried to get a DEA registration but was denied because she’s excluded from Medicare and other federal health programs. She didn’t ask for a hearing, so the denial stands. This means she can’t legally handle controlled substances, affecting her work and income starting now.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Denied for Itaman
The Drug Enforcement Administration denied Honorata Anna Itaman's application for a DEA Certificate of Registration (Control No. W24026383M). The Order is effective February 17, 2026, and the denial means she cannot hold a DEA registration and therefore cannot legally possess or handle controlled substances, which affects her ability to work and earn income.
Exclusion Blocks DEA Registration
The DEA may deny an application for registration when an applicant has been excluded from Medicare, Medicaid, or all federal health care programs under 42 U.S.C. 1320a-7(a). In this case, HHS/OIG mandatorily excluded the applicant effective September 19, 2024 for a period of 11 years, and the DEA relied on that exclusion as a statutory basis to deny the registration.
Default for No Hearing Request
If an applicant does not file a written request for a hearing in response to an Order to Show Cause, the applicant is deemed in default and is treated as admitting the factual allegations, which can lead to a final denial. The record shows the applicant did not request a hearing and was therefore deemed in default, leading to denial.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-00622 — Proviso Railroad, Inc.-Acquisition Exemption-L. Neill Cartage Co., Inc.
Proviso Railroad, Inc. is set to take over and operate a short rail line owned by L. Neill Cartage Co. in Berkeley, Illinois, used for moving goods like paper and lumber. This change kicks in on January 29, 2026, with no big money shifts expected since Proviso’s revenue stays small. The move keeps future rail connections open and promises smooth cargo swaps with Union Pacific Railroad.
Next: 2026-00624 — Mason Railroad, Inc.-Acquisition Exemption-L. Neill Cartage Co., Inc.
Mason Railroad, Inc. is set to take over and operate a short rail line owned by L. Neill Cartage Co. in Bedford Park, Illinois, starting January 29, 2026. This line helps move bulk goods like paper and lumber by connecting with a bigger railway. The deal won’t change future rail connections and won’t bring big money changes, keeping things smooth and local.